KILITCH — Kilitch Drugs (India) Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual income statement for Kilitch Drugs (India), fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	685	1,142	1,396	1,544	1,983
Cost of Revenue
Gross Profit	243	392	489	575	689
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	653	1,056	1,256	1,334	1,694
Operating Profit	32.3	86.2	140	210	290
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	51.2	96.1	120	194	345
Provision for Income Taxes
Net Income After Taxes	37.7	62.1	82.8	136	249
Minority Interest
Net Income Before Extraordinary Items
Net Income	36.7	73.7	104	146	267
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	36.7	73.7	104	146	267
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.32	5.16	7.09	9.49	16.8